Evaluating Time to Pain Progression in Multiple Myeloma

In conclusion, lower deterioration thresholds result in more frequent and durable events. However, patients often deteriorate, improve, and then deteriorate again. As patients may remain on clinical trials for long periods, researchers interested in assessing time to the first (durable) deterioration should clearly justify this approach. Additionally, the assessment of deterioration durability may be complicated by measures such as the use of opioid analgesia, vertebroplasty, and palliative radiotherapy. As pain is an important myeloma symptom and capturing the patient's experience while on therapy is critical, further research to better characterize patient pain while on trial is needed.DisclosuresKing-Kallimanis: Pharmerit International: Employment.

Source: Blood - November 21, 2018 Category: Hematology Authors: Roydhouse, J. K., Bhatnagar, V., Fiero, M. H., King-Kallimanis, B. L., Suzman, D. L., Singh, H., Daniels, S., Kluetz, P. Tags: 904. Outcomes Research-Malignant Conditions: Poster I Source Type: research